Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Ce...( Small Molecule Stem Cell Modulator Ad...),Health

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy

LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate. The study, which is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, will determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow.

"The mission of Fate Therapeutics is to develop small molecules and biologics that modulate adult stem cells within the body for regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "As our first SCM clinical candidate, FT1050 represents the initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo regenerative effect. With FT1050, we are trying to affect stem cell biology in the body, improving the reconstitution of a patient's blood and immune system."

"For patients who need hematopoietic stem cell support, time is of the essence," said Corey Cutler M.D., M.P.H., F.R.C.P.C., assistant professor of medicine, Dana-Farber and Harvard Medical School, and leader of the clinical study. "However, many patients do not have a suitably matched donor, either from a sibling or from an unrelated volunteer in t
'/>"/>